

### Point of Care Technology: Why Knowing Now Matters in The ED





Ellis Jacobs, Ph.D., DABCC, FACB Director, Scientific Affairs, Alere Inc. Adjunct Associate Professor of Pathology, Mount Sinai School of Medicine

AACC NY Metro Section / Trimark POCT Conference Memorial Sloan Kettering Cancer Center, New York, NY September 14, 2017



1 Emergency Department Facts and Figures

2 Knowing now matters<sup>™</sup> for Chest Pain


3 Knowing now matters<sup>™</sup> for Sepsis

4 Knowing now matters<sup>™</sup> for Infectious Disease

There are data in this presentation that are taken from individual published studies. They are individual evaluations and are not meant to replace or represent Alere product claims which are found in the package inserts.



#### >136 MM ED visits = 44.5 visits/100 persons/year




http://www.cdc.gov/nchs/data/ahcd/nhamcs\_emergency/2011\_ed\_web\_tables.pdf



#### >136 MM ED visits = 44.5 visits/100 persons/year

#### % of EDs





Approximately three-quarters of emergency room (ER) physicians have seen increases in patient visits since January 2014.



in volume.

In addition to a national shortage of primary care doctors, experts cite a lack of physicians willing to accept Medicaid patients as contributing factors to increased ER usage.

7 in 10 survey respondents to a ACEP survey say their emergency departments are not ready for continuing, and potentially significant, increases

<sup>1</sup>USA Today 5/4/2015 http://www.usatoday.com/story/news/nation/2015/05/04/ emergency-room-visits-rise-under-affordable-care-act/26625571/

### Alere Delay in the ED Leads to Poor Outcomes

# 71%-79%

higher likelihood of death when ED length of stay is greater than 6 hours<sup>1</sup>

# 20% increase

in risk of death for every hour an ED patient waits<sup>2</sup>

# 10% increase

In risk of death for a one hour increase in overall length of ED stay<sup>2</sup> Long ED stay leads to worse adherence to ACC/AHA guideline care for NSTEMI patients<sup>3</sup>

Aspirin

**ß-blockers** 


Heparin

GP II/IIIa inhibitors


Clopidigrel


<sup>1.</sup>BMJ (2011) **342:** d2983 <sup>2</sup> MJA (2006) **182:** 208-212 <sup>3</sup> Ann Emerg Med. (2007); **50;** 489-96

### Alere Theoretical TAT Impact on ED Operations




#### AVG. PATIENTS SEEN/DAY





#### **DIVERSION HOURS/DAY**










### Knowing now matters<sup>™</sup> in the ED Chest Pain

Alere Challenges in Chest Pain Triage



For patients 45+ years old, non-specific chest pain is the most common ED presentation resulting in discharge



Heart	Gastro- intestinal	Lung	Muscle/ Bone	Other
Heart attack	Acid reflux	Pneumonia	Bruised or broken	Shingles
Angina	(heartburn)	Viral bronchitis	ribs	Panic attack
Pericarditis	Swallowing problems related	Pneumothorax	Sore muscles from exertion or	
Myocarditis	to disorders of the esophagus		chronic pain syndromes	
Cardiomyopathy	Gallstones or		Compression	
Aortic dissection	inflammation of the gallbladder or pancreas		fracture, causing pressure on a nerve	

## Alere NSTEMIs Are Not Just Chest Pain

#### **Commonly:**

- Chest pain or discomfort
- Upper body discomfort
- Shortness of breath

#### But consider...

- Pain and discomfort could be mild, and could come and go over hours
- Diabetics may have no, or very mild, symptoms
- Cold sweat
- Nausea and vomiting
- Light-headedness or sudden dizziness


#### Women:

- Feeling unusually tired for no reason, sometimes for days
- Pain in the back, shoulders, and jaw



# Some NSTEMIs have no symptoms at all







#### **OBSERVATION**

### DISCHARGE

# CATH LAB

**ADMIT** 

### Alere Universal Definition of MI

#### (Joint ESC/ACCF/AHA/WHF Task Force)

# Mis: Myocardial necrosis in a clinical setting consistent with myocardial ischemia

Rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile with at least one of the following:

- Symptoms of ischemia
- New or presumed new significant ST-segment changes or new left bundle branch block
- Development of pathological Q waves in the ECG
- Imaging evidence: loss of myocardium or wall motion abnormality
- ID of intracoronary thrombus by angiography or autopsy

Cardiac death with symptoms of ischemia

PCI patients: Cardiac marker elevations of 5 x 99th percentile or rise of 20%

Stent thrombosis identified by angiography or autopsy

CABG patients: Cardiac marker elevations of 10 x 99th percentile

# Alere Important to Remember



#### A positive Tn is no longer an MI

# A positive Tn means cardiac damage

- It could be an MI
- It could be something else...

# Alere Non-ACS/HF Tn Elevations

#### **Cardiac and Vascular**

- Acute aortic dissection
- Cerebrovascular accident
  - Ischemic stroke
  - Intracerebral hemorrhage
  - Subarachnoid hemorrhage

#### Respiratory

Acute PE, ARDS

#### Muscular Damage

#### **Cardiac Inflammation**

 Endocarditis, Myocarditis, Pericarditis

#### Infectious

 Sepsis, Viral illness, Kawasaki disease. Apical ballooning syndrome. Thrombotic thrombocytopenic purpura, Rhabdomyolysis, Birth complications in infants (low birth weight, preterm)

#### Acute Complications of Inherited Disorders

 Neurofibromatosis, Duchenne muscular dystrophy, Klippel-Feil syndrome

#### **Environmental Exposure**

 Carbon monoxide, Hydrogen sulfide, Colchicine

#### **Chronic Disease**

 ESRD, Cardiac infiltrative disorders (Amyloidosis, Sarcoidosis, Hemochromatosis), Scleroderma, Hypertension, Diabetes, Hyperthyroidism

#### **latrogenic Disease**


- Invasive procedures (Heart transplant, Congenital defect repair, Lung resection, ERCP, RFCA)
- Noninvasive procedures (Cardioversion, Lithotripsy)
- Pharmacological sources (Chemotherapy, Other medications)

#### **Myocardial Injury**

 Blunt chest injury, Endurance athletes, Envenomation (Snake, Jellyfish, Spider, Centipede, Scorpion)

# Alere How to Best Use ThI Results

**99th Percentile Value:** Apparently healthy population, results are typically close to zero **AMI Cutoff:** Value that determines if a patient is experiencing an AMI based on WHO criteria



Serial draws are recommended to detect temporal rise and fall of troponin-l levels characteristic of MI, and should be used in conjunction with other information such as other cardiac markers, ECG, clinical symptoms, etc.

# Alere How to Best Use ThI Results

**99th Percentile Value:** Apparently healthy population, results are typically close to zero **AMI Cutoff:** Value that determines if a patient is experiencing an AMI based on WHO criteria



Serial draws are recommended to detect temporal rise and fall of troponin-I levels characteristic of MI, and should be used in conjunction with other information such as other cardiac markers, ECG, clinical symptoms, etc.

The American College of Emergency Physicians (ACEP) Alere Guidelines for Non-ST Elevation Chest Pain Patients


#### **All patients**

- No rule-in recommendation.
- For rule-out: A single negative CK-MB mass, Troponin I or Troponin T measured 8-12 hours after symptom onset.

#### Early presenters (<6-8 hours after symptom onset)

- A negative myoglobin in conjunction with a negative CK-MB mass, or negative Troponin when measured at baseline and 90 minutes.
- A negative 2-hour delta CK-MB mass in conjunction with a negative 2-hour delta Troponin.

Alere How to Best Use Thi Results



Hours After Onset of MI

FOR DISCUSSION PURPOSES ONLY. The temporal release patterns of modern troponin assays have not been conclusively established in the literature. Individual patients may exhibit unique cardiac marker profiles.

### Alere Rapid Disposition Algorithm and Strategy

#### Data from three Dallas-area hospitals:

#### Medical Center of Arlington

~ one hour intervals

#### **Plaza Medical Center**

~ two-hour intervals

#### **Medical City Dallas**

~ three hour intervals

# If any of the three criteria below were met, the patient was considered positive for an MI:



A TnI  $\geq$  0.4 ng/mL on any draw



A doubling of myoglobin between sequential draws with any detectable TnI by the last draw



A doubling of myoglobin between sequential draws with a 50% or greater increase in CK-MB without detectable TnI on any of the draws

# Testing performed on the Alere Triage platform.



	SINGLE DRAW		SERIAL DRAWS	
	0.05 ng/mL	0.4 ng/mL	0.05 ng/mL	0.4 ng/mL
Sensitivity (%)	79.7	57.4	97.3	68.2
Specificity (%)	96.1	99.8	95.0	99.8
Accuracy (%)	95.6	98.6	95.1	98.9
PPV (%)	37.2	87.6	36.4	89.4
NPV (%)	99.4	98.8	99.9	99.1

Alere Clinical Value of Rapid Disposition Algorithm

5,24	1
patients	


# 30,087

test results generated


**1.9** draws per patient

**5.7** test results

per patient




### Improving Patient Flow in Acute Coronary Syndromes Alere in the Face of Hospital Crowding



#### In the post-implementation period there was:

- 20% reduction in hospital LOS.
- 33% reduction in ED LOS
- 62% decrease (5% vs. 1.9%) in 30-day mortality

Alere POCT Alone is Not Enough



Ę



	Admitted	Discharged
Disposition	-7.8 minutes	–20.4 minutes
Departure	↓ −9 minutes	–7.2 minutes






# Knowing now matters<sup>™</sup> in the ED Sepsis




#### Systemic, deleterious host response to infection

 Presence (probable or documented) of infection together with systemic manifestations of infection which may include:




### Alere Mortality Rates

- Sepsis remains the leading cause of death in critically ill patients in the United States.
- Each year 750,000 people will develop sepsis.
- Leading non-cardiac cause of death in ICUs
- Mortality rates between 28-38%






Infection, documented or suspected, and some of the following:







# Initial Resuscitation and Infection Issues-

Protocolized resuscitation of patients with sepsisinduced hypoperfusion

- Hypotension after initial fluid challenge or
- Lactate > 4 mmol/L

6-hour goals

- CVP 8-12 mm Hg
- MAP > 65 mm Hg
- Urine output
   >0.5 mL\* kg\*hr
- ScvO<sub>2</sub> 70% or SvO<sub>2</sub> 65%

Normalize an elevated lactate

### Alere Improve Patient Outcomes

- Lactate clearance is associated with improved patient outcome.
- Lactate measurement is associated with increased risk of death independent of other aspects of sepsis bundle guidelines.
- Point-of-care measurements of lactate are faster than central laboratories.
  - May be beneficial for serial measurements.




Nguyen HB, Rivers EP, Knoblich BP *et al.* Crit Care Med. (2004) **32**:1637-42. Afessa B, Keegan MT, Schramm GE *et al.* Crit Care Med. (2011) **15(Suppl 1):** P286. Boldt J, Kumle B, Suttner S *et al.* Acta Anaesthesiol Scand. (2001) **45**:194–9. Alere Implementation of the Surviving Sepsis Protocols

15,775 patients at 252 participating Surviving Sepsis sites<sup>1</sup>


Unadjusted **hospital mortality decreased** from 37% to 30.8% over a 2-year period

<sup>1</sup>Intensive Care Med (2010) **36**:222-231.





Alere Implementation of the Surviving Sepsis Protocols



<sup>2</sup>. Crit Care Med (2011) **39:**252-258,

<sup>3</sup>. Ann Pharmacother (2010) **44:**1733-1738

## Rapid Lactates for Septic Patients: Alere CMS Core Measure

- SEP-1: Early Management Bundle, Severe Sepsis/Septic Shock Specifications Manual for National Hospital Inpatient Quality Measures
- Discharges 10-01-15 (4Q15) through 06-30-16 (2Q16) SEP-3

Severe Sepsis	Septic Shock
Within 3 hours of presentation time, patient must have:	Within 3 hours of presentation time, patient must have:
<ul> <li>Lactate drawn</li> <li>Blood cultures drawn</li> <li>Broad-spectrum antibiotics administered</li> <li>Within 6 hours of presentation time:</li> <li>Repeat lactate must be drawn if the initial lactate was &gt;2.0 mmol/L</li> </ul>	<ul> <li>Resuscitation with 30ml/kg of crystalloid fluid for hypotension or lactate ≥4 mmol /liter</li> <li>Within 6 hours of presentation time (and only if hypotension persists after fluid administration):         <ul> <li>Vasopressors</li> <li>Reassessment of volume status and tissue perfusion must be documented in the medical record</li> </ul> </li> </ul>

#### **INITIATED ON OCTOBER 1, 2015**

## Alere Point-of-Care Analyte Benefits

- A 2010 study published in the Journal of Emergency Medicine found that point-of-care testing provided a reliable and feasible way to measure serum lactate at the bedside.<sup>1</sup>
- Point-of-care lactate is useful in the diagnosis of sepsis at the bedside
  - Recommended for institutions where clinical decisions are limited by lack of laboratory infrastructure or reliability.<sup>2</sup>



<sup>1</sup>Shapiro NI, Fisher C, Donnino M *et al.* J Emerg Med. (2010) **39:**89-94. <sup>2</sup>Moore CC, Jacob ST, Pinkerton R *et al.* Clin Infect Dis. (2008) **46:**215-22.

## Alere Turnaround Time

- Serum lactate must be available with rapid turnaround time (within minutes) to effectively treat severely septic patients.
- An arterial blood gas analyzer located in the clinical laboratories usually accomplishes this.
- Hospitals should invest in adequate equipment in to meet present standards of care for septic patients.




# Alere Don't Forget Creatinine

Prior to any imaging procedure that requires the use of a contrast dye, an measurement of creatinine levels is required to confirm kidney function.

POC creatinine can play a key role in these diagnostic pathways.








# Knowing now matters<sup>™</sup> in the ED Infectious Disease

#### Advantages of Rapid Testing for Alere Infectious Diseases


# Better directed therapy<br/>to reduceLess adverse<br/>consequencesReduced length-of-stay<br/>in emergency<br/>departmentantibiotic resistanthospital length-of-stay


Timely application of appropriate Infection control procedures

#### Teachable moment




■ MD unaware, n =92 ■ MD aware, n=97






■ MD unaware, n =106 ■ MD aware, n=96




## Alere Key Operational Metrics



#### \* p ≤ 0.001





Without amplification, a positive test might not be detected.

Dipsticks

Readers

45

Cards

## Alere Flu Clinical Trial Results: vs PCR


#### Alere<sup>™</sup> i Influenza A & B against RT-PCR for Influenza A

Alere <sup>™</sup> i Influenza A & B – Flu A		RT-PCR	
	Positive	Negative	Total
Positive	147	11	158
Negative	8	464	472
Total	155	475	630
Positive Percent Agreement: 14 Negative Percent Agreement: 40		(95%CI: 90.1%–97.4%) (95%CI: 95.9%–98.7%)	

#### Alere<sup>™</sup> i Influenza A & B against RT-PCR for Influenza B

Alere <sup>™</sup> i Influenza A & B – Flu B		RT-PCR	
	Positive	Negative	Total
Positive	123	3	126
Negative	2	500	502
Total	125	503	628
Positive Percent Agreement: 12 Negative Percent Agreement: 5		(95%CI: 94.4%–99.6%) (95%CI: 98.3%–99.8%)	

#### Alere Every Minute Counts at the Point of Care






#### Knowledge of a Positive Test Has Been Shown to:

- Limit unnecessary antibiotic use
- Limit unnecessary diagnostic procedures
- Increase the appropriate use of antivirals



Alere<sup>™</sup> i is *significantly faster* than other molecular methods and more accurate than conventional rapid testing giving you the *confidence* to make effective *patient management decisions sooner*.

## Alere Summary of the Recommendations



- Routine screening in all healthcare settings with undiagnosed prevalence ≥0.1% for patients aged 13 to 64 years
- Repeat testing should be performed at least annually for those determined to be high-risk
- Routine screening for all pregnant women
- Screening should be voluntary using opt-out consent

## Alere ACEP 2014 Policy Statement

Corby diagraphic and	Prolongs life	
Early diagnosis and treatment of HIV	Reduces transmission	
	Is a cost-effective public health intervention	

ED HIV screening programs are best when:	Local prevalence of HIV is > 0.1%
	Procedures are practical and feasible
	<ul> <li>Integrated with resources of the healthcare system (linkage to care)</li> </ul>

## Alere Is Rapid Testing in the ED Feasible?

#### PROS

- High-risk populations use the ED as their sole source for medical care
- Seroprevalence is relatively high (≥ 0.1% per CDC guidance) and this affords an outstanding opportunity to determine risk and to test for HIV
- Rapid tests are quick and accurate
- Growing experience and body of literature demonstrating clinical and cost effectiveness

#### CONS

- Perceptions regarding ED-based prevention efforts vary
- Program implementation will vary depending on resources and site
- Limited comparative data
- Funding

## Alere Benefits of Early Diagnosis of HIV Infection


#### Reduction of high-risk behavior<sup>1</sup>

#### **Reduces the risk of forward transmission:**

Individuals with acute HIV infection are 43 times more contagious than chronically infected HIV patients<sup>2</sup>

## Allows individuals with HIV to seek treatment earlier which:<sup>3,4,5</sup>

- Will improve their health
- Reduces the risk of premature death
- Reduces their viral load, reducing the risk of forward transmission




<sup>1</sup>Marks G, *et al.* JAIDS (2005) **39:**446-453
<sup>2</sup>Pinkerton, S.D. AIDS Behav. (2008 September) **12:** 677–684. doi:10.1007/s10461-007-9329-1.
<sup>3</sup>Moyer VA, *et al.* Ann Intern Med. (2013) **159:**51-60.
<sup>4</sup>CDC. MMWR (2011) ;60(47):1618–23.
<sup>5</sup>Starting antiretroviral treatment early improves outcomes for HIV infected individuals.

http://www.nih.gov/news/health/may2015/niaid-27.htm

## Performance of Alere Determine<sup>™</sup> HIV-1/2 Alere Ag/Ab Combo

#### Number of Early HIV Infection Samples Identified (confirmed by NAAT)







## Is POCT in the ED Cost Effective?

## Alere Is POCT Cost Effective?

Review article covering the value of POCT for:

ACS

VTE

Sepsis

Stroke

with respect to the numerous manual steps to be performed in transferring a blood sample to the central laboratory and to retrieve the results consecutively, the total costs of POCT devices tend not to exceed those of central analysis.

POC staff do need to learn how to operate the POCT, but expediting patient flow might reduce the strain on this staff.

When used effectively and in the appropriate context, POCT has been shown to reduce delays to treatment initiation in the critically ill, improve outcomes, increase timely patient discharge rates, and decrease total length of stay. Elevated costs of POCT per analysis seem to be outweighed by the total gain of expedited patient flow in the appropriate setting.





#### **Questions?**

© 2017 Alere. All rights reserved. The Alere Logo, Alere, Clearview, Determine and Knowing now matters are trademarks of the Alere group of companies. All other trademarks referenced are trademarks of their respective owners. SAHIGHR-0068 vC 01/17